AstraZeneca receives CDSCO panel nod to conduct phase 3 trial of Trastuzumab Deruxtecan
Advertisement
In a significant development, major drug-maker AstraZeneca has got the go ahead from the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) to conduct a Phase 3 clinical trial of oncology drug Trastuzumab Deruxtecan, which is an antibody used to treat certain types of unresectable or metastatic HER-2 positive breast cancer.
This comes in the wake of the Phase III clinical trial protocol presented by AstraZeneca at the recent SEC meeting for Oncology and Haematology.
For more details, check out the full story on the link below:
AstraZeneca Gets CDSCO Panel Nod To Conduct Cancer Drug Trastuzumab Deruxtecan Study
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.